APA (7th ed.) Citation

Decker, T., Brucker, C., Engel, A., Fasching, P. A., Göhler, T., Jackisch, C., . . . Wöckel, A. (2025). Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: Real-world data from the RIBANNA study. ESMO open, 10(6), . https://doi.org/10.1016/j.esmoop.2025.105105

Chicago Style (17th ed.) Citation

Decker, Thomas, et al. "Conditional Progression-free Survival in Patients with Metastatic Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Breast Cancer Treated with First-line Ribociclib and Endocrine Therapy: Real-world Data from the RIBANNA Study." ESMO Open 10, no. 6 (2025). https://doi.org/10.1016/j.esmoop.2025.105105.

MLA (9th ed.) Citation

Decker, Thomas, et al. "Conditional Progression-free Survival in Patients with Metastatic Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Breast Cancer Treated with First-line Ribociclib and Endocrine Therapy: Real-world Data from the RIBANNA Study." ESMO Open, vol. 10, no. 6, 2025, https://doi.org/10.1016/j.esmoop.2025.105105.